Company: ANTX
Filing Date: 2025-05-13
Form Type: 10-Q
Source: 0000950170-25-070358
Chunk: 10

Company: AN2 Therapeutics, Inc.
Filing Date: 2025-05-13
Form: 10-Q
Item: Item 5
Chunk 10
---
On March 31, 2025, Gilbert Lynn Marks, a member of our board of directors, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 20,000 shares of our common stock until May 15, 2026.

On March 31, 2025, Eric Easom, our Chief Executive Officer and a member of our board of directors, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 450,000 shares of our common stock until December 31, 2025.

During the fiscal quarter ended March 31, 2025, none of our other directors or officers (as defined in Section 16 of the Securities Exchange Act of 1934, as amended) adopted, modified, or terminated any contract, instruction or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any “non-Rule 10b5-1 trading arrangement,” as defined in Item 408(c) of Regulation S-K.